A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

From Europe to Africa to North America to Australia, measles cases are rising across continents. The main driver: declining vaccination rates and immunity gaps.

As of March 26, 1,575 confirmed measles cases were reported in the United States in 2026, according to the latest data published by the US Centers for Disease Control and Prevention.

There have been 16 new outbreaks reported in 2026, and 94% of confirmed cases (1,483 of 1,575) are outbreak-associated (359 from outbreaks starting in 2026 and 1,124 from outbreaks that started in 2025). In 92 percent of cases, measles occurred among those with no vaccination.

Mexico's Ministry of Health recently reported a significant increase in measles cases in 2026, with more than 7,400 confirmed infections recorded since the beginning of the year.

A PAHO report in February shared a 43-fold increase in measles cases across seven countries — Bolivia, Canada, Chile, the United States, Guatemala, Mexico, and Uruguay — with no deaths reported.

Active outbreaks have been reported in London and Birmingham in the UK. In Europe, recurring outbreaks have been reported in Italy, Spain, France and Romania.

A measles alert has also been issued for the Gold Coast area after two cases were confirmed to have been contracted by people overseas and then brought home to Australia.

Earlier this week, Bangladesh reported a measles outbreak that reportedly led to the death of at least 38 children, leading health authorities to roll out a vaccination program for younger children in a bid to halt the outbreak.

Official data show that in 2026, more than 2,300 children were admitted to hospital with suspected measles, of whom 684 have tested positive so far.

Amid these outbreaks, HealthandMe spoke to public health experts to understand whether these cases can increase the risk of the highly contagious disease in India. While India has a better vaccination rate with the Measles and Rubella (MR) Vaccine, some pockets in rural areas may increase the risk.

"In India, the catch-up vaccination drive named Mission Indradhanush was intensified in 2024, successfully rectifying the vaccination gaps that occurred during the COVID pandemic. But the disease can still spread among pockets of the population where vaccination coverage remains low,” Dr. Rajeev Jayadevan, Ex-President of IMA Cochin and Convener of the Research Cell, Kerala, told HealthandMe.

"The proven method to stop measles is to build an 'immunity wall' within the community—by vaccinating at least 95 percent of people—so that the virus repeatedly runs into 'road blocks' and eventually dies out, instead of getting a free ride infecting everyone. When vaccination coverage drops due to many reasons, outbreaks happen, and complications follow," he added.

Also read: Measles In Oahu Visitor Sparks Exposure Risk In Hawaii: Report

What Is Measles?

Measles is a highly contagious virus that spreads through direct contact or through the air when an infected person coughs or sneezes.

Symptoms typically appear seven to 14 days after exposure and may include:

high fever,

cough,

runny nose,

red eyes,

rashes across the body.

Measles And Vaccination

Measles is a vaccine-preventable disease that can cause devastating complications, including blindness, pneumonia, encephalitis, and long-term immune dysfunction.

The reports of deaths from Bangladesh indicate the presence of a significant 'immunity gap,” allowing the virus to take hold, said Dr. Jayadevan. He added that among the unvaccinated, measles is one of the most contagious viruses on Earth—spreading even faster than COVID-19.

Dr Neha Rastogi, Senior Consultant - Infectious Diseases, Fortis Gurugram, told HealthandMe that although the Measles-Rubella (MR) vaccination campaign has played a major role in reducing cases and preventing large-scale outbreaks by building community immunity in India, "there is still some risk of Measles spread in India".

"Although cases have declined significantly, outbreaks can occur due to gaps in vaccination coverage, especially in rural or densely populated areas. Migration, low awareness, and missed immunization doses also contribute to the risk,” she added.

How Does Measles Spread

"Measles spreads rapidly because it is a highly contagious viral disease transmitted through respiratory droplets when an infected person coughs or sneezes," Dr Rastogi told HealthandMe.

She noted that crowded living conditions, poor ventilation, and low immunity levels increase the risk of transmission.

"Lack of awareness, malnutrition (especially vitamin A deficiency), and incomplete or missed vaccination also contribute to outbreaks. The virus can remain active in the air or on surfaces for several hours, making it easy to infect others,” the infectious disease expert said.

The CDC noted that measles transmission may also occur during travel.

"Travelers with fever and other overt signs of transmissible illness, such as coughing or malaise, should be strongly encouraged to delay travel while symptomatic,” it said.

Dr. Jayadevan said that the rising global measles cases are "a reminder that no one is safe until everyone is safe. India must strive to identify those pockets where vaccination coverage is low and undertake intensive corrective measures, taking the community into confidence through effective awareness campaigns".

How To Stay Safe

To safeguard against measles, individuals should ensure timely vaccination, especially for children.

Maintaining good hygiene, such as frequent handwashing and covering the mouth while coughing or sneezing, helps reduce transmission.

Avoiding close contact with infected individuals and ensuring proper nutrition to boost immunity are also important.

Public awareness and community health programs play a crucial role in prevention.

In a disturbing case from the US state of Florida, a pregnant woman in active labor was forced to attend a virtual court hearing via Zoom from her hospital bed for refusing a Cesarean delivery, also known as C-section — a common method of childbirth.

ProPublica reported that Cherise Doyley was in her 12th hour of contractions at the University of Florida Health facility, when she was, without her consent, made to sit in front of a host of people — a judge in a black robe and several lawyers, doctors, and hospital staff — for the Zoom proceeding.

While in active labor, a nurse came in with a bedsheet and told her to cover up, and a supervisor followed with a tablet.

“It’s a real judge in there?” Doyley asked the nurse at the beginning of what would be a three-hour hearing.

What Was The Case?

The mother of three, and a professional birthing doula, Doyley had arrived at the facility after her water broke.

While her doctors expressed concerns about the risk of uterine rupture —a potentially deadly complication for her and her baby — Doyley wanted to try for a vaginal delivery, as the risk was less than 2 percent, unless there was an emergency.

She told doctors she wouldn’t consent to a cesarean without trying to have a vaginal delivery first.

While the doctors initially relented, after several hours, she had to face a virtual court hearing, where the hospital and state attorney’s office forced Doyley to undergo a cesarean section.

Doyley has her own reasons to avoid a C-sec. She already had three prior C-sections, and one that resulted in a hemorrhage. She feared that a C-sec would lead to another serious complication and a lengthy recovery, and her kids would suffer.

However, the hospital was worried that her medical decisions may cause harm to the fetus, and that the courts may help decide which one mattered more, the report said.

Also read: Maternal Vaccination During Pregnancy Can Prevent COVID-related Hospitalization In Babies: Study

After three hours of testimony — all while Doyley lay in her hospital bed — the judge ruled that she could keep laboring unless there was an emergency. If that happened, the hospital could operate, whether she wanted it or not.

Overnight, doctors said the baby’s heart rate dropped for seven minutes. Doyley woke to her hospital bed being wheeled into surgery. The baby girl was delivered by C-section, the report said.

What Happens In A C-section?

It is a surgical procedure that is used to deliver a baby through an incision made in the abdomen and uterus.

The method is preferred, especially in cases with complications during labor or breech presentation, or multiple births.

Unlike the popular conception, it hurts. In a vaginal delivery, the pain is experienced during labor and pushing, especially if done without an epidural.

Whereas, in a C-section, a surgery is performed that numbs the body from the chest down. However, the recovery could be painful and prolonged. It is also because in a C-section, it involves healing from a major abdominal surgery, while vaginal birth recovery may be quicker, more complicated, or traumatic.

Also read: 'Husband Stitch': A Medical Necessity Or Just A Tool To Objectify Women's Bodies?

Does A C-sec Affect The Baby?

Usually, it does not harm the baby, but there could be potential risks to the baby, including:

• Surgical injury, which is very rare; however, the baby may be accidentally nicked during the incision.

• Respiratory issues: Babies born via C-section may have a higher risk of breathing, since they miss the natural compression during the vaginal birth that helps expel the amniotic fluid from their lungs

• Delayed bonding: Immediate skin-to-skin contact may take longer due to the surgical process.
• Feeding challenges: Some newborns may initially struggle with breastfeeding.

Risks Of A C-section Birth?

• Excessive blood loss
• Infection
• Blood clots in the legs, lungs, or pelvis
• Damage to nearby organs
• Adverse reactions to anesthesia

The American College of Obstetricians and Gynecologists (ACOG) advises against elective C-sections due to these potential complications.

American drugmaker Eli Lilly’s first oral pill for weight loss, Orforglipron, marketed as Foundayo, has been given the green signal by the US Food and Drug Administration (FDA).

Lilly is also known for injectable drugs like Zepbound for obesity and Mounjaro and Trulicity for diabetes.

Foundayo’s approval comes after the US FDA in December last year approved Novo Nordisk’s Wegovy pill — the first-ever GLP-1 pill for weight loss. The Danish drugmaker rolled out the pill in January this year.

Novo Nordisk was also the first to launch oral GLP 1 Rybelsus to treat type 2 diabetes. It was approved by the US FDA in September 2019.

Also Read: World Autism Awareness Day 2026: Can Cell Therapy Be The Future Of Autism Treatment?

In a statement, the US FDA said that "Foundayo has been approved for use in combination with a reduced-calorie diet and increased physical activity. The pill is targeted to reduce excess body weight and maintain weight reduction for the long term in adults with obesity or overweight".

Lilly said that the drug will be available from April 6 through its its direct-to-consumer platform LillyDirect at a cost of $149 per month for the lowest dose for self-pay customers — on par with Novo's pill. "Shortly after” it will be available through retail pharmacies and telehealth providers in the US.

"Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity, or the belief that their condition isn't serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," said David A. Ricks, chair and CEO of Eli Lilly and Company.

"As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world," he added.

Foundayo: A Meaningful Reduction In Body Weight

Also Read: Foundayo: US FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill

In these trials, 72 weeks of treatment with Foundayo, in combination with a reduced-calorie diet and increased physical activity, resulted in a statistically significant and clinically meaningful reduction in body weight.

Deborah Horn, Director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, stated that Foundayo “delivered an average of 12.4 percent weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day."

In addition, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses, Eli Lilly said.

How Foundayo Works

Lilly licensed Orforglipron, the main ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.

As with the injectable forms of GLP-1s, Foundayo is available in six doses, ranging from 0.8mg to 17.2mg.

In consultation with their doctors, patients start with the lowest dose and gradually work up to higher doses; not everyone may need to reach the highest dose.

Also read: Eli Lilly's Experimental GLP-1 Pill Shows Promising Weight Loss

Unlike the Wegovy pill, people taking orforglipron do not need to restrict food or drink after taking the pill. Orforglipron is a small molecule that the body can absorb quickly and get into the blood, where it reaches the necessary tissues.

Foundayo: Side Effects

Foundayo is not safe for use in children and has an increased list of side effects, such as tumors in the thyroid, including thyroid cancer.

The drugmaker urged watching for possible symptoms, such as

• a lump or swelling in the neck,
• hoarseness,
• trouble swallowing
• shortness of breath.

• nausea,
• constipation,
• diarrhea,
• vomiting,
• indigestion,
• stomach (abdominal) pain,
• headache,
• swollen belly,
• feeling tired,
• belching,
• heartburn,
• gas,
• hair loss.